Cargando…

Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker

Metallothioneins (MT) are low molecular weight, cysteine-rich proteins maintaining metal ions homeostasis. They play a role in carcinogenesis and may also cause chemoresistance. The aim of the study was to explore the importance of MT serum levels in children suffering from malignant tumours. This p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kruseova, Jarmila, Hynek, David, Adam, Vojtech, Kizek, Rene, Prusa, Richard, Hrabeta, Jan, Eckschlager, Tomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709780/
https://www.ncbi.nlm.nih.gov/pubmed/23743828
http://dx.doi.org/10.3390/ijms140612170
_version_ 1782276801843691520
author Kruseova, Jarmila
Hynek, David
Adam, Vojtech
Kizek, Rene
Prusa, Richard
Hrabeta, Jan
Eckschlager, Tomas
author_facet Kruseova, Jarmila
Hynek, David
Adam, Vojtech
Kizek, Rene
Prusa, Richard
Hrabeta, Jan
Eckschlager, Tomas
author_sort Kruseova, Jarmila
collection PubMed
description Metallothioneins (MT) are low molecular weight, cysteine-rich proteins maintaining metal ions homeostasis. They play a role in carcinogenesis and may also cause chemoresistance. The aim of the study was to explore the importance of MT serum levels in children suffering from malignant tumours. This prospective study involves examination of 865 samples from 172 patients with malignant tumours treated from 2008 to 2011 at University Hospital Motol. MT serum levels were determined using differential pulse voltammetry–Brdicka reaction. Mean MT level was 2.7 ± 0.5 μM. There was no statistically significant difference between MT levels in different tumours. We also did not find any correlation between MT levels and response to therapy or clinical stages. However, we found a positive correlation between MT levels and age (p = 0.009) and a negative correlation with absolute lymphocyte number (p = 0.001). The fact that patients who had early disease recurrence had lower MT levels during the treatment (complete remission 2.67 vs. recurring 2.34, p = 0.001) seems to be important for clinical practice. Accordingly we believe that there is benefit in further studies of serum MT levels in tumours.
format Online
Article
Text
id pubmed-3709780
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-37097802013-07-12 Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker Kruseova, Jarmila Hynek, David Adam, Vojtech Kizek, Rene Prusa, Richard Hrabeta, Jan Eckschlager, Tomas Int J Mol Sci Article Metallothioneins (MT) are low molecular weight, cysteine-rich proteins maintaining metal ions homeostasis. They play a role in carcinogenesis and may also cause chemoresistance. The aim of the study was to explore the importance of MT serum levels in children suffering from malignant tumours. This prospective study involves examination of 865 samples from 172 patients with malignant tumours treated from 2008 to 2011 at University Hospital Motol. MT serum levels were determined using differential pulse voltammetry–Brdicka reaction. Mean MT level was 2.7 ± 0.5 μM. There was no statistically significant difference between MT levels in different tumours. We also did not find any correlation between MT levels and response to therapy or clinical stages. However, we found a positive correlation between MT levels and age (p = 0.009) and a negative correlation with absolute lymphocyte number (p = 0.001). The fact that patients who had early disease recurrence had lower MT levels during the treatment (complete remission 2.67 vs. recurring 2.34, p = 0.001) seems to be important for clinical practice. Accordingly we believe that there is benefit in further studies of serum MT levels in tumours. Molecular Diversity Preservation International (MDPI) 2013-06-06 /pmc/articles/PMC3709780/ /pubmed/23743828 http://dx.doi.org/10.3390/ijms140612170 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Kruseova, Jarmila
Hynek, David
Adam, Vojtech
Kizek, Rene
Prusa, Richard
Hrabeta, Jan
Eckschlager, Tomas
Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker
title Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker
title_full Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker
title_fullStr Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker
title_full_unstemmed Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker
title_short Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker
title_sort serum metallothioneins in childhood tumours—a potential prognostic marker
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709780/
https://www.ncbi.nlm.nih.gov/pubmed/23743828
http://dx.doi.org/10.3390/ijms140612170
work_keys_str_mv AT kruseovajarmila serummetallothioneinsinchildhoodtumoursapotentialprognosticmarker
AT hynekdavid serummetallothioneinsinchildhoodtumoursapotentialprognosticmarker
AT adamvojtech serummetallothioneinsinchildhoodtumoursapotentialprognosticmarker
AT kizekrene serummetallothioneinsinchildhoodtumoursapotentialprognosticmarker
AT prusarichard serummetallothioneinsinchildhoodtumoursapotentialprognosticmarker
AT hrabetajan serummetallothioneinsinchildhoodtumoursapotentialprognosticmarker
AT eckschlagertomas serummetallothioneinsinchildhoodtumoursapotentialprognosticmarker